# Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

> **NCT01794793** · PHASE4 · COMPLETED · sponsor: **RECORDATI GROUP** · enrollment: 337 (actual)

## Conditions studied

- Cushing's Disease
- Acromegaly
- Neuroendocrine Tumors
- Pituitary Tumors
- Ectopic ACTH Secreting (EAS) Tumors
- Dumping Syndrome
- Prostate Cancer
- Melanoma Negative for bRAF
- Melanoma Negative for nRAS

## Interventions

- **DRUG:** Pasireotide
- **DRUG:** Cabergoline
- **DRUG:** Pasireotide LAR

## Key facts

- **NCT ID:** NCT01794793
- **Lead sponsor:** RECORDATI GROUP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-10
- **Primary completion:** 2023-07-25
- **Final completion:** 2023-07-25
- **Target enrollment:** 337 (ACTUAL)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01794793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01794793, "Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01794793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*